NASDAQ$EOLS
Evolus Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Evolus achieved record revenue and made strides toward profitability.
Evolus reported a record fourth quarter global net revenue of $61.0 million, representing a 40% increase compared to the same period last year. The company also generated $0.8 million of cash from operating activities and significantly reduced its non-GAAP operating loss to $3.7 million.
- Global net revenue reached a record $61.0 million, a 40% increase year-over-year.
- Generated $0.8M of Cash from Operating Activities.
- Non-GAAP operating loss improved to $3.7 million, the lowest since inception.
- Accounts purchasing Jeuveau® increased by a record high of more than 840.
Headline financials
Revenue & EPS history
Evolus · Revenue · Quarterly
$61M
Forward guidance
Evolus expects total net revenues for the full year 2024 to be between $255 and $265 million and expects to achieve positive non-GAAP operating income on a consolidated basis for the fourth quarter of 2024 and for the full year 2025.
Tailwinds
- Evolus expects total net revenues for the full year 2024 to be between $255 and $265 million, representing year-over-year growth of 26% to 31% from 2023 results and well above the estimated growth rate of the aesthetic neurotoxin market.
- Evolus expects its adjusted gross profit margin for the full year 2024 to be between 68% and 71%, consistent with 2023 guidance.
- Evolus expects its full-year non-GAAP operating expenses to be between $185 and $190 million.
- The company expects to achieve positive non-GAAP operating income on a consolidated basis for the fourth quarter of 2024 and for the full year 2025.
- The company projects its total net revenue can reach at least $700 million by 2028, a compound annual growth rate of 28% from 2023, based on the combination of its existing aesthetic neurotoxin business and anticipated launch of the Evolysse™ HA dermal filler product line beginning in 2025.
Headwinds
- Within the year 2025, profitability may not be sustained every quarter due to the filler launch.
- The company’s forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements.
- Uncertainties associated with the company’s ability to comply with the terms and conditions in the Medytox Settlement Agreements.
- Unfavorable global economic conditions and the impact on consumer discretionary spending.
- Uncertainties related to customer and consumer adoption of Jeuveau® and EvolysseTM
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
+0.5%
Avg return
Earnings day
-0.8%
Avg return
5 days after
+0.1%
Avg return
30 days after
42%
14 / 33 earnings
Positive
+35.4%
Q4 2025
Best reaction
-26.9%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.7% | +19.3% | — | |
| Q4 2025 | +35.4% | +29.5% | -2.4% | |
| Q3 2025 | +5.4% | +2.6% | +0.6% | |
| Q1 2025 | -14.2% | -13.9% | -14.6% | |
| Q4 2024 | -1.3% | -11.6% | -25.5% | |
| Q3 2024 | -13.3% | -20.4% | -23.2% | |
| Q2 2024 | +15.2% | +9.2% | +30.4% | |
| Q1 2024 | -1.0% | -4.8% | -7.4% | |
| Q4 2023 | -0.3% | -0.1% | -6.0% | |
| Q3 2023 | +9.7% | +0.4% | +20.3% | |
| Q2 2023 | -1.2% | -8.3% | -2.6% | |
| Q1 2023 | +17.8% | +14.9% | -3.9% | |
| Q4 2022 | -6.4% | -7.7% | -8.5% | |
| Q3 2022 | -8.4% | -3.2% | -1.6% | |
| Q2 2022 | -26.9% | -28.3% | -30.3% | |
| Q1 2022 | +9.2% | +29.0% | +20.4% | |
| Q4 2021 | +1.8% | +3.0% | +25.0% | |
| Q3 2021 | -9.5% | -10.0% | -33.3% | |
| Q2 2021 | -6.9% | +1.7% | -15.1% | |
| Q1 2021 | -0.9% | +2.4% | +41.1% | |
| Q4 2020 | -21.1% | -28.2% | -43.0% | |
| Q3 2020 | -1.9% | +2.3% | +23.9% | |
| Q2 2020 | +6.6% | +6.0% | +2.6% | |
| Q1 2020 | +4.8% | -9.7% | +32.9% | |
| Q4 2019 | -3.4% | -8.1% | -51.9% | |
| Q3 2019 | -2.2% | -10.7% | -20.3% | |
| Q2 2019 | -10.9% | -21.8% | -6.7% | |
| Q1 2019 | -7.5% | -5.1% | -46.4% | |
| Q4 2018 | +7.0% | -3.3% | -2.7% | |
| Q3 2018 | -5.8% | -6.6% | -10.6% | |
| Q2 2018 | +6.0% | +8.2% | +34.8% | |
| Q1 2018 | +27.9% | +38.9% | +142.4% | |
| Q4 2017 | +8.5% | +9.1% | -15.3% | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro